Daily BriefsEvent-Driven

Daily Brief Event-Driven: Nikkei 225 Index Rebalance: Oriental Land and more

In today’s briefing:

  • Nikkei 225 Index Rebalance: Oriental Land, Renesas, JAL IN; Toyobo, Nippon LightMetal, Toho Zinc OUT
  • Nikkei 225 March 2023 Review – OLC, JAL, Renesas IN.
  • Yashili (1230 HK): ​Mengniu Offer Imminent As Key Sale Concludes
  • Quiddity ASX Rebal Mar 23: Good Hit Rate, Some Short Buildup, Decent Impact
  • Yashili (1230 HK): Pre-Condition Satisfaction Likely Within 5 Business Days
  • UnitedHealth/​EMIS: Estimated Calendar, Spread

Nikkei 225 Index Rebalance: Oriental Land, Renesas, JAL IN; Toyobo, Nippon LightMetal, Toho Zinc OUT

By Brian Freitas


Nikkei 225 March 2023 Review – OLC, JAL, Renesas IN.

By Travis Lundy


Yashili (1230 HK): ​Mengniu Offer Imminent As Key Sale Concludes

By David Blennerhassett


Quiddity ASX Rebal Mar 23: Good Hit Rate, Some Short Buildup, Decent Impact

By Janaghan Jeyakumar, CFA

  • The index changes for the ASX Index family for the March 2023 Rebalance were announced after the close on Friday 3rd March 2023.
  • There will be one, two, and four changes for ASX 20, ASX 100, and ASX 200 indices, respectively. There will also be 12 ADDs and 9 DELs for ASX 300.
  • In this insight, we take a closer look at our expectations for index flows, short interest, and recent price performance of the names involved in the rebalance event.

Yashili (1230 HK): Pre-Condition Satisfaction Likely Within 5 Business Days

By Arun George

  • Yashili International Holdings (1230 HK) announced that the Dumex China Disposal was completed. The completion will result in the satisfaction of the last pre-condition, likely within five business days.
  • China Mengniu Dairy Co (2319 HK)’s offer is HK$1.20 per share. Due to the upcoming release of full-year results, the scheme document will be likely despatched by early April. 
  • This is a done deal and timing is the key risk. At the current price and for a late-May payment, the gross and annualised spread is 2.6% and 11.3%, respectively.

UnitedHealth/​EMIS: Estimated Calendar, Spread

By Jesus Rodriguez Aguilar

  • A CMA’s Phase One investigation period began on 23 January to investigate whether the deal may result in a substantial lessening of competition. Deadline for the decision is 17 March.
  • EMIS anticipates closing late Q1/early Q2 2023. The Permitted Final Dividend amounts to 21.1p. No final dividend has yet been declared, although theoretically it could happen around 17 March.
  • Spread is 2.96%/29.39% (gross/annualised), assuming settlement by 15 April, as good as it gets for a stock with an average daily turnover of c.GBP7 million in the European space.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars